成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 1453-82-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1453-82-3
Chemical Structure| 1453-82-3
Structure of 1453-82-3 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 1453-82-3 ]

Related Doc. of [ 1453-82-3 ]

Alternatived Products of [ 1453-82-3 ]
Product Citations

Product Citations      Expand+

Hegde, Pooja Venkatesh ;

Abstract: Tuberculosis (TB) remains a leading cause of infectious disease mortality and morbidity resulting in nearly 1.3 million deaths annually and infecting nearly one-quarter of the population. Chapter 1 discusses the epidemiology, control, and management of TB. Isoniazid (INH) is a cornerstone for the treatment of drug-susceptible TB, yet the quantitative structure-activity relationships for INH are not well documented in the literature. Chapter 2 evaluates a systematic series of INH analogs against contemporary Mycobacterium tuberculosis (Mtb) strains from different lineages and several key species of non-tuberculous mycobacteria (NTM). To assess the specific activity of this series of INH analogs against mycobacteria, we assayed them against a panel of Gram-positive and Gram-negative bacteria, as well as a number of fungi. Our findings provide an updated analysis of the structure-activity relationship of INH that will serve as a valuable resource for the development of a next generation antitubercular compounds. para-Aminosalicylic acid (PAS), is an important second-line agent for treating drug-resistant Mtb. PAS has a moderate bioavailability and rapid clearance that necessitate high doses in order to facilitate an effective treatment. Consequently, such high doses commonly results in gastrointestinal disturbances (presumably by disruption of gut microbiota and host epithelial cells). Chapter 3 discusses the design, synthesis and evaluation of PAS prodrugs and analogs with improved oral bioavailability, thereby preventing intestinal accumulation as well as undesirable bioactivation by the gut microbiome to cytotoxic folate species. The pivoxyl prodrug and fluorination at the 5- position address the primary limitations of PAS and have the potential to revitalize this second-line TB drug. vi Pyrazinamide (PZA) is a critical component of the first-line TB treatment regimen because of its sterilizing activity against non-replicating Mtb, but its mechanism of action has remained enigmatic. PZA is a prodrug converted to the active moiety- pyrazinoic acid (POA), by pyrazinamidase, an amidase within the nicotinamide adenine dinucleotide (NAD) salvage pathway encoded by pncA in Mtb. PZA resistance is most commonly induced via loss-of-function mutations within PncA. It has recently been demonstrated that POA induces targeted protein degradation of the enzyme PanD, a crucial component of the coenzyme A biosynthetic pathway, essential in Mtb. Chapter 4 describes the structure activity relationship (SAR) evaluation of various POA analogs. Further development and mechanistic analysis of these analogs may lead to a next generation POA analog for treating TB. The salicylic acid derived small molecule siderophores known as mycobactins are essential for mycobacterial iron acquisition and mycobactin biosynthesis has been biochemically and genetically validated as essential for survival in vivo. Sal-AMS, a modified nucleoside derivative that mimics an intermediate in the mycobactin biosynthetic pathway, is a potent Mtb inhibitor. Chapter 5 explores polyfluorinated salicylic acid derivatives as antimetabolites, designed to antagonize mycobactin synthesis. Enzymatic studies demonstrated that the tri- and tetra- fluorinated salicylic acid analogs were neither substrates nor inhibitors of MbtA, but the di-fluorinated compounds were readily activated by the bifunctional adenylating enzyme MbtA, responsible for processing salicylic acid moieties for synthesis of mycobactins. However further microbiological analysis revealed that the polyfluorinated derivatives have low potential as anti-TB agents and do not appear to operate by inhibiting mycobactin synthesis. vii Lastly, the chemical synthesis of nucleoside analogs, an important class of compounds with applications as anti-infective, anti-cancer, and diagnostic agents, is extremely challenging, typically requiring linear synthesis, multiple protectiondeprotection sequences, and stereoselective formation of the critical glycosidic linkage. Nucleoside phosphorylases (NPs) have tremendous biocatalytic potential and aid in the selective modification of nucleosides under green conditions. Chapter 6 focuses on the functional characterization of 15 thermostable purine NPs. Four of these were further selected for a comprehensive analysis of their substrate scope. Next, chemoenzymatic methods for the synthesis of modified nucleosides were extensively studied using various coupled systems, and 12 modified nucleosides were synthesized, isolated, and characterized. viii Table of Contents Acknowledgments......................

Purchased from AmBeed: ; ; ; ; ; ;

Hegde, Pooja ; Boshoff, Helena I. M. ; Rusman, Yudi , et al. DOI: PubMed ID:

Abstract: Isoniazid (INH) remains a cornerstone for treatment of drug susceptible tuberculosis (TB), yet the quant. structure-activity relationships for INH are not well documented in the literature. In this paper, we have evaluated a systematic series of INH analogs against contemporary Mycobacterium tuberculosis strains from different lineages and a few non-tuberculous mycobacteria (NTM). Deletion of the pyridyl nitrogen atom, isomerization of the pyridine nitrogen to other positions, replacement of the pyridine ring with isosteric heterocycles, and modification of the hydrazide moiety of INH abolishes antitubercular activity. Similarly, substitution of the pyridine ring at the 3-position is not tolerated while substitution at the 2-position is permitted with 2-methyl-INH 9 displaying antimycobacterial activity comparable to INH. To assess the specific activity of this series of INH analogs against mycobacteria, we assayed them against a panel of gram-pos. and gram-neg. bacteria, as well as a few fungi. As expected INH and its analogs display a narrow spectrum of activity and are inactive against all non-mycobacterial strains evaluated, except for 4, which has modest inhibitory activity against Cryptococcus neoformans. Our findings provide an updated anal. of the structure-activity relationship of INH that we hope will serve as useful resource for the community.

Keywords: Isoniazid ; SAR

Purchased from AmBeed: ; ; ; ; 54-92-2 ; ; ;

Product Details of [ 1453-82-3 ]

CAS No. :1453-82-3 MDL No. :MFCD00006432
Formula : C6H6N2O Boiling Point : No data available
Linear Structure Formula :C5H4N(C(O)NH2) InChI Key :VFQXVTODMYMSMJ-UHFFFAOYSA-N
M.W : 122.12 Pubchem ID :15074
Synonyms :

Calculated chemistry of [ 1453-82-3 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 32.33
TPSA : 55.98 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.24 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.65
Log Po/w (XLOGP3) : -0.28
Log Po/w (WLOGP) : 0.18
Log Po/w (MLOGP) : -0.43
Log Po/w (SILICOS-IT) : 0.52
Consensus Log Po/w : 0.13

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.85
Solubility : 17.3 mg/ml ; 0.142 mol/l
Class : Very soluble
Log S (Ali) : -0.44
Solubility : 44.7 mg/ml ; 0.366 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.57
Solubility : 3.3 mg/ml ; 0.027 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 1453-82-3 ]

Signal Word:Warning Class:
Precautionary Statements:P261-P305+P351+P338 UN#:
Hazard Statements:H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 1453-82-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1453-82-3 ]

[ 1453-82-3 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 313368-91-1 ]
  • [ 1453-82-3 ]
  • 1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3‘,4‘:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)butan-1-one isonicotinamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
In methanol; at 20℃; for 2h; The slurry experiment in methanol is repeated at a gram scale. First, ITI-007 free base and isonicotinamide are each dissolved in methanol. Subsequently, the obtained solutionsare mixed in a 1:1 ratio and the resulting mixture is stirred at room temperature for 2 hours. The mixture remains a clear solution, which is evaporated under vacuum to give a brown sticky solid. XRPD analysis shows the brown sticky solid to be crystalline, as shown in Figure 1, ITI-007 free base-isonicotinamide co-crystal has formed. The corresponding peak list is showing in Table 1.The XRPD shows clustered peaks which is likely due to preferred orientation.
  • 2
  • [ 1453-82-3 ]
  • [ 34259-99-9 ]
  • N-(thiazol-4-yl)isonicotinamide [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 1453-82-3 ]

Amides

Chemical Structure| 251101-36-7

[ 251101-36-7 ]

3-Methylisonicotinamide

Similarity: 0.90

Chemical Structure| 64188-97-2

[ 64188-97-2 ]

3-Aminoisonicotinamide

Similarity: 0.87

Chemical Structure| 54-92-2

[ 54-92-2 ]

N'-Isopropylisonicotinohydrazide

Similarity: 0.83

Chemical Structure| 4663-99-4

[ 4663-99-4 ]

Pyridine-3,5-dicarboxamide

Similarity: 0.83

Chemical Structure| 58539-65-4

[ 58539-65-4 ]

2-Methylnicotinamide

Similarity: 0.81

Amines

Chemical Structure| 251101-36-7

[ 251101-36-7 ]

3-Methylisonicotinamide

Similarity: 0.90

Chemical Structure| 64188-97-2

[ 64188-97-2 ]

3-Aminoisonicotinamide

Similarity: 0.87

Chemical Structure| 54-92-2

[ 54-92-2 ]

N'-Isopropylisonicotinohydrazide

Similarity: 0.83

Chemical Structure| 4663-99-4

[ 4663-99-4 ]

Pyridine-3,5-dicarboxamide

Similarity: 0.83

Chemical Structure| 58539-65-4

[ 58539-65-4 ]

2-Methylnicotinamide

Similarity: 0.81

Related Parent Nucleus of
[ 1453-82-3 ]

Pyridines

Chemical Structure| 251101-36-7

[ 251101-36-7 ]

3-Methylisonicotinamide

Similarity: 0.90

Chemical Structure| 64188-97-2

[ 64188-97-2 ]

3-Aminoisonicotinamide

Similarity: 0.87

Chemical Structure| 54-92-2

[ 54-92-2 ]

N'-Isopropylisonicotinohydrazide

Similarity: 0.83

Chemical Structure| 4663-99-4

[ 4663-99-4 ]

Pyridine-3,5-dicarboxamide

Similarity: 0.83

Chemical Structure| 58539-65-4

[ 58539-65-4 ]

2-Methylnicotinamide

Similarity: 0.81

; ;